CytoDyn Retains Gibraltar Associates for Corporate and Investor Communications
<0> Gibraltar AssociatesVice PresidentCaitlin Carroll(202) 258-9118 </0>
CytoDyn Inc. (the "Company") (CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has retained Gibraltar Associates for corporate communications and investor relations services. Gibraltar will offer integrated consulting services to highlight CytoDyn’s development of monoclonal antibody therapies for the treatment of HIV and other infectious diseases, as well as increase the Company's visibility with the institutional investor community.
"With one monoclonal antibody in development for the treatment of HIV infection in humans and the other in felines, we believe this is the right time to launch a comprehensive communications plan to educate the market regarding monoclonal antibodies as potential new therapies to treat HIV infection as well as identify high-quality institutional investors,” said Dr. Nader Pourhassan, interim President and CEO of CytoDyn. "Gibraltar provides our company with elite talent and expertise in investor and public relations. We are turning to them to help us to tell our story and focus on improving shareholder value."
"Our experience in repositioning corporate brands, navigating public affairs challenges, and unlocking shareholder value promises to create a successful partnership with CytoDyn," said Eric Bovim, CEO of Gibraltar Associates. "We look forward to working with CytoDyn in communicating the substantial market potential for monoclonal antibody therapies as a new breed of HIV treatment options, and highlighting CytoDyn’s established position in the industry."
The Company is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. The Company's proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. The Company intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. In addition, the Company is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. The Company recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and the Company please go to .
Gibraltar Associates is a consultancy specializing in risk and reputation management, public affairs and business development for clients worldwide. Gibraltar Associates blends expertise from diverse consulting genres to offer clients a truly holistic approach to solving challenges confronting the business. Our mission is to provide world-class counsel to clients and implement those ideas to produce a tangible business result. The company is based in Washington, D.C., with an office in Los Angeles. For more information, please visit: or call 202-879-5808.
This press release includes forward-looking statements and includes forward-looking information within the meaning of United States securities laws. These statements and this information represent the Company's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, many of which are beyond the Company's control. These factors could cause actual results to differ materially from such forward-looking statements or forward-looking information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or on this forward-looking information.